At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Apr 13, 2026 at 16:01 ET
Revolution Medicines announced two concurrent capital raises: a $750 million common stock offering and a $250 million convertible note offering due 2033, with over-allotment options totaling $150 million. The offerings are not contingent on each other, and proceeds will fund R&D and potential commercialization of its RAS-targeted oncology pipeline.
- Company is conducting a $750 million common stock offering and a $250 million convertible senior notes offering due 2033.
- Underwriters have 30-day options to purchase up to an additional $112.5 million in stock and $37.5 million in notes.
- Offerings are not contingent on each other.
- Net proceeds will be used for R&D, commercialization planning, general corporate purposes, and capital expenditures.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access